

1. This document is an English translation of the official Japanese text of "Notice Regarding Acquisition of Shares of USM HEALTHCARE MEDICAL DEVICES FACTORY JOINT STOCK COMPANY, a Medical Devices Manufacturer in Vietnam, and Making It a Subsidiary".
2. In the event of any discrepancies between this translation and the Japanese original, the original shall prevail.

January 23rd, 2026

Junya Suzuki
Chairman of the Board and Group CEO
Nissha Co., Ltd.

Stock Exchange Listing: Tokyo Stock Exchange, Prime Market 7915
Contact: Daisuke Inoue
Director of the Board, Senior Executive Vice President, Interim CFO
T +81 75 811 8111

Notice Regarding Acquisition of Shares of USM HEALTHCARE MEDICAL DEVICES FACTORY JOINT STOCK COMPANY, a Medical Devices Manufacturer in Vietnam, and Making It a Subsidiary

Nissha Co., Ltd. ("the Company"), pursuant to a resolution of the Board of Directors meeting held on January 23, 2026, has decided to acquire shares in USM HEALTHCARE MEDICAL DEVICES FACTORY JOINT STOCK COMPANY ("USM Healthcare"), a medical devices manufacturer based in Ho Chi Minh City, Vietnam. Following the acquisition, USM Healthcare will become a subsidiary of the Company.

Additionally, USM Healthcare is scheduled to be classified as a specified subsidiary of the Company after the share acquisition, as the value of capital stock of USM Healthcare is greater than 10% of the capital stock of the Company.

1. Reason for the acquisition of stock

The Company has established a long-term vision and aims to create economic and social value by solving global social issues related to medical, mobility, and sustainable markets, by integrating and orchestrating of diverse talents of our employees and technologies. The Company aims to increase the ratio of consolidated net sales which is constituted by the medical market to 50% by 2030, and to achieve business expansion through company-wide efforts, with the Company having set its sights on the areas of medical devices, pharmaceuticals, and healthcare products.

USM Healthcare is engaged in the manufacturing and sale of products such as stents used in cardiology (devices used in catheter-based treatments that are minimally invasive) and devices used in orthopedics. USM Healthcare has a vertically integrated system in place which encompasses processes spanning from product design and development to regulatory approval, manufacturing, and sales, giving the company a competitive edge in terms of pricing. As Vietnam's only domestic manufacturer in the stent field, USM Healthcare has continued to grow in recent years on the back of preferential policies aimed at domestic medical devices in Vietnam, and is thus anticipated to enjoy further growth in the future. Moreover, USM Healthcare is leveraging its capabilities in the areas of product design, development and manufacturing in relation to the services it provides to medical device manufacturers, and is developing its contract design/development and manufacturing organization (CDMO) for medical devices.

The medical devices market in Southeast Asia, including Vietnam, is rapidly expanding against the backdrop of economic development and improved standards of medical care. There is increased demand for medical devices offering high levels of quality and superior cost efficiency, meaning that the market is expected to see further growth in the future. With a focus on the US, the most advanced country when it comes to medical devices, the Company has leveraged its advanced capabilities in the areas of design, development and manufacturing in relation to areas such as surgical instruments for minimally invasive medical care, and has aimed to expand its business regarding CDMO for medical devices. Together with the Company's continuation of business expansion in the US, the establishment of a

new subsidiary taking place on this occasion means that the Company will be acquiring a new business base for medical device manufacturing in the Asia region. Taking full advantage of the Nisssha Group's customer bases in the US and Japan, the Group's knowledge on design, development and manufacturing in relation to CDMO for medical devices, as well as its quality management, the Company will proceed with strengthening the existing businesses of USM Healthcare and making them more efficient while also promoting the geographic expansion of CDMO for medical devices in Southeast Asia.

2. Method of acquisition

The Company and Nisssha Vietnam Co., Ltd., which is a local Vietnamese corporation of the Nisssha Group, will acquire 60% of the issued shares of USM Healthcare and turn the aforementioned company into a subsidiary. The Company will be acquiring 59.99% of the issued shares of USM Healthcare and Nisssha Vietnam Co., Ltd. will be acquiring the remaining 0.01%.

3. Outline of Subsidiary to Acquire Share

(Nisssha Vietnam Co., Ltd.)

(1) Name	Nisssha Vietnam Co., Ltd.
(2) Location	Room 4, Vit Tower 9F, 519 Kim Ma, Ba Dinh, Hanoi, Vietnam
(3) Position and name of representative	Yutaka Nishimoto (Director/Company President)
(4) Scope of business	Business management hub in Vietnam
(5) Capital stock	4,248,008,700 Vietnamese dong
(6) Date of foundation	December 16, 2016
(7) Major shareholders and ratio of shares held	Nisssha Precision and Technologies, Inc.: 100%

4. Outline of Subsidiary to be Transferred

(USM HEALTHCARE MEDICAL DEVICES FACTORY JOINT STOCK COMPANY)

(1) Name	USM HEALTHCARE MEDICAL DEVICES FACTORY JOINT STOCK COMPANY		
(2) Location	Saigon Hi-tech Park, Long Thanh My Ward, HCMC		
(3) Position and name of representative	VÕ XUÂN BỘI LÂM		
(4) Scope of business	Manufacturing and sale of medical devices		
(5) Capital stock	282,681,280,000 Vietnamese dong		
(6) Date of foundation	October 2012		
(7) Major shareholders and ratio of shares held	VÕ XUÂN BỘI LÂM: 48.82%, EastBridge: 25.71%, Other: 25.47%		
(8) Relationship between the listed company and the aforementioned company	Capital relationship	There are no capital relationships to be reported.	
	Interpersonal relationship	There are no interpersonal relationships to be reported.	
	Transactional relationship	There are no transactional relationships to be reported.	
(9) Operating results and financial condition of the aforementioned company for the latest three fiscal years (Unit: Million Vietnamese dong)			
Fiscal year-end	December 31, 2022	December 31, 2023	December 31, 2024
Net assets	791,016	802,400	803,604
Total assets	1,121,681	1,083,980	1,095,735
Net sales	552,646	267,218	321,909
Profit attributable to owners of parent	55,252	13,063	1,480

5. Outline of Counterparty to Share Acquisition

(1) VÕ XUÂN BỘI LÂM

(1) Name	VÕ XUÂN BỘI LÂM
(2) Location	Ho Chi Minh City, Vietnam
(3) Relationship between the listed company and the aforementioned individual	There are no items to report.

(2) TRAN THI NGOC THUY

(1) Name	TRAN THI NGOC THUY
(2) Location	Ho Chi Minh City, Vietnam
(3) Relationship between the listed company and the aforementioned individual	There are no items to report.

(3) HUYNH NGOC TRIEN

(1) Name	HUYNH NGOC TRIEN
(2) Location	Ho Chi Minh City, Vietnam
(3) Relationship between the listed company and the aforementioned individual	There are no items to report.

(4) VO XUAN QUANG

(1) Name	VO XUAN QUANG
(2) Location	Ho Chi Minh City, Vietnam
(3) Relationship between the listed company and the aforementioned individual	There are no items to report.

(5) NGUYEN THI NGOC DUNG

(1) Name	NGUYEN THI NGOC DUNG
(2) Location	Ho Chi Minh City, Vietnam
(3) Relationship between the listed company and the aforementioned individual	There are no items to report.

(6) Eastbridge Asia PEF

(1) Name	Eastbridge Asia PEF
(2) Location	South Korea
(3) Grounds for establishment, etc.	Limited Partnership
(4) Purpose of formation	A private equity fund specializing in high growth companies based in Korea and Southeast Asia.
(5) Year of formation	2021
(6) Total contribution amounts	Not disclosed due to confidentiality obligations
(7) Investors and investment ratios • Overview of investors	Not disclosed due to confidentiality obligations

(8) Overview of the managing general partner	Name	Eastbridge Partners
	Location	South Korea
	Position and name of representative	Not disclosed due to confidentiality obligations
	Business details	General partner of private equity funds
	Capital	Not disclosed due to confidentiality obligations
(9) Overview of the domestic agent	Name	NA
	Location	
	Position and name of representative	
	Business details	
	Capital	
(10) Relationship between the listed company and the fund in question	Relationships between the listed company and the fund in question	Neither the Company, nor any of its affiliates or related parties, has made any direct or indirect investments in the fund. There are not reportable capital, personnel, or business relationships between the Company, its affiliates and related parties, and the investors of the fund.
	Relationships between the listed company and the managing general partner	There is no reportable capital, personnel, or business relationships between the Company, including its affiliates and related parties, and operating partners of the fund, including their affiliates and related parties.
	Relationships between the listed company and the domestic agent	NA

(7) SEA Women's Economic Empowerment Fund ("SWEEF")

(1) Name	SEA Women's Economic Empowerment Fund ("SWEEF")	
(2) Location	Singapore	
(3) Grounds for establishment, etc.	Sub fund of Sweef Capital VCC	
(4) Purpose of formation	Fund vehicle to make investments on behalf of the SWEEF limited partners in investments advancing women's economic empowerment across Vietnam, Indonesia and the Philippines.	
(5) Year of formation	2020	
(6) Total contribution amounts	Not disclosed due to confidentiality obligations	
(7) Investors and investment ratios • Overview of investors	Not disclosed due to confidentiality obligations	
	Name	SWEEF GP Pte Ltd
(8) Overview of the managing general partner	Location	Singapore
	Position and name of representative	Jennifer Buckley Authorised representative
	Business details	Investment management
	Capital	Not disclosed due to confidentiality obligations

(9) Overview of the domestic agent	Name	NA
	Location	
	Position and name of representative	
	Business details	
	Capital	
(10) Relationship between the listed company and the fund in question	Relationships between the listed company and the fund in question	Neither the Company, nor any of its affiliates or related parties, has made any direct or indirect investment in the fund. There are no reportable capital, personnel, or business relationships between the Company, its affiliates and related parties, and the investors of the fund
	Relationships between the listed company and the managing general partner	There are no reportable capital, personnel, or business relationships between the Company, including its affiliates and related parties, and operating partners of the fund, including their affiliates and related parties.
	Relationships between the listed company and the domestic agent	NA

6. Number of shares to be acquired, acquisition price, and the number of shares held after the acquisition

(1) Number of shares held before transfer	0 (Number of voting rights: 0 units)
(2) Number of shares to be acquired	16,960,877 (Number of voting rights: 16,960,877 units)
(3) Acquisition price	At the request of the transaction partner, the acquisition price has not been disclosed. However, the price was decided in a rational manner upon mutual consultation which was undertaken based primarily on the DCF method, with the Company having commissioned a valuation conducted by a third-party organization as part of that process.
(4) Number of shares held after transfer	16,960,877 (Number of voting rights: 16,960,877 units)

7. Schedule

(1) Approval date by the Board of Directors' meeting	January 23, 2026
(2) Date of execution of the agreement	January 23, 2026
(3) Date of implementation of the share transfer	March 2026 (Scheduled)

8. Outlook for the future

The impact of the acquisition on the Company's consolidated financial results is minor.

END